Antimicrobial activity of acrylic intraocular lenses soaked in fourth generation fluoroquinolones.
OBJECTIVE
The aim of this study was to determine whether a commercially available brand of intraocular lenses (IOLs) soaked in moxifloxacin or gatifloxacin for 1 or 60 min have antimicrobial properties.


METHODS
The IOLs (N = 8-10/group) were soaked in saline, physiologic-strength moxifloxacin (1.8 microg/mL), or gatifloxacin (0.48 microg/mL) for 60 min or commercial-strength moxifloxacin (5 mg/mL) or gatifloxacin (3 mg/mL) for 1 or 60 min. Presoaked IOLs and gatifloxacin antibiotic disks were plated on agar with quality-controlled ATCC 25923 Staphylococcus aureus overlay. Bacterial kill zones were measured after 24 h.


RESULTS
IOLs soaked in physiologic-strength gatifloxacin or saline for 60 min produced no measurable bacterial kill zone, and the mean bacterial kill zone for IOLs soaked in physiologic-strength moxifloxacin was significantly greater (P = 0.011, 0 vs. 3.88 +/- 3.18 mm, respectively). Soaking the IOLs in commercial-strength moxifloxacin or gatifloxacin for 1 or 60 min produced significantly larger bacterial kill zones (P < 0.0001, mean: > or =33 mm for all groups). Soaking for 1 min produced a significantly larger mean bacterial kill zone by moxifloxacinthan gatifloxacin-treated IOLs (P = 0.002, 38.80 +/- 3.74 mm, 34.30 +/- 1.34 mm, respectively). The mean bacterial kill zone was significantly larger for IOLs soaked in commercial-strength moxifloxacin for 1 versus 60 min (P = 0.002, 38.80 +/- 3.74 mm, 33.56 +/- 1.42 mm, respectively). There was no significant difference in the mean bacterial kill zone between IOLs soaked for 1 or 60 min in commercial-strength gatifloxacin (34.30 +/- 1.34 mm, 33.67 +/- 0.50 mm, respectively).
Smith
Edward F
EF
SUNY Downstate Department of Ophthalmology, SUNY Downstate Medical Center, Brooklyn, NY 11217, USA. esmith6960@aol.com
Elbash
Abdel Rahman
AR
Schrier
Amilia
A
Berg
Peter D
PD
Eid
Issa
I
D000180:Acrylic Resins; D000287:Administration, Topical; D000900:Anti-Bacterial Agents / Q000008:administration & dosage* / Q000493:pharmacokinetics; D001082:Aqueous Humor / Q000378:metabolism; D001372:Aza Compounds / Q000008:administration & dosage / Q000493:pharmacokinetics; D016503:Drug Delivery Systems; D024841:Fluoroquinolones / Q000008:administration & dosage* / Q000493:pharmacokinetics; D000077734:Gatifloxacin; D066298:In Vitro Techniques; D007910:Lenses, Intraocular; D000077266:Moxifloxacin; D011804:Quinolines / Q000008:administration & dosage / Q000493:pharmacokinetics; D013211:Staphylococcus aureus / Q000187:drug effects / Q000302:isolation & purification
D000180:Acrylic Resins; D000900:Anti-Bacterial Agents; D001372:Aza Compounds; D024841:Fluoroquinolones; D011804:Quinolines; D000077734:Gatifloxacin; D000077266:Moxifloxacin